All In Biotech

Drug Trial Radar · NCT04206605

A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)

A Phase 3, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)

Last checked: Nov 20, 2026Latest source record: Dec 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

77

Actual

Start

May 4, 2020

Primary completion

Oct 20, 2022

Study completion Oct 20, 2022

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
Collaborators
Takeda Development Center Americas, Inc.
First posted
Dec 20, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main aim of this study is to check if repeated subcutaneous (SC) injections of lanadelumab can prevent angioedema attacks in teenagers and adults with non-histaminergic angioedema with normal C1-INH. Another aim is to check if they tolerate the repeated SC injections. Participants will receive a SC injection of lanadelumab every two weeks for 26 weeks. The first two doses of lanadelumab will be given at the study clinic. Once a participant (and/or parent/caregiver) has been appropriately trained, lanadelumab can be self-injected. Visits to the study clinic are planned for the first, third and fourth week and then every 4 weeks.

Conditions

  • Angioedema

Interventions

  • PlaceboOther

    Placebo-matching lanadelumab SC injection.

  • LanadelumabDrug

    Lanadelumab solution in a PFS for injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Investigator-Confirmed Angioedema Attacks During the Treatment Period of Day 0 Through Day 182Time frame: Day 0 through Day 182

Locations

45 sites in 10 countries. Site status is shown where the registry gives one.

  • Clinical Research Center of Alabama

    Birmingham, Alabama

  • Medical Research of Arizona

    Scottsdale, Arizona

  • University of California San Diego

    San Diego, California

  • AIRE Medical of Los Angeles

    Santa Monica, California

  • Allergy and Asthma Clinical Research Inc

    Walnut Creek, California

  • Asthma and Allergy Associates, PC

    Colorado Springs, Colorado

  • University of South Florida Asthma, Allergy & Immunology

    Tampa, Florida

  • Rush University Medical Center

    Chicago, Illinois

  • Kanarek Allergy, Asthma and Immunology

    Overland Park, Kansas

  • Institute for Asthma & Allergy - Chevy Chase

    Chevy Chase, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Mayo Clinic - Rochester

    Rochester, Minnesota

  • Washington University

    St Louis, Missouri

  • Jay M Kashkin, MD Allergy, Asthma and Immunology

    Fair Lawn, New Jersey

  • Clinical Research of Charlotte

    Charlotte, North Carolina

  • Bernstein Clinical Research Center, LLC

    Cincinnati, Ohio

  • Optimed Research, LTD

    Columbus, Ohio

  • Tanner Clinic

    Layton, Utah

  • Seattle Allergy & Asthma Research Institute

    Seattle, Washington

  • Ottawa Allergy Research Corporation

    Ottawa, Ontario, Canada

  • Clinique Specialisee en Allergie de la Capitale

    Québec, Quebec, Canada

  • CHU Grenoble Alpes, service de médecine interne, bureau de recherche clinique

    Isere, France

  • Service médecine interne, hôpital Saint Antoine

    Paris, France

  • Klinikum rechts der Isar der TUM, HNO Klinik und Poliklinik

    Munich, Germany

  • Klinikum der Johann Wolfgang Goethe-Universitaet

    Frankfurt am Main, Hesse, Germany

  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz

    Mainz, Rhineland-Palatinate, Germany

  • Universitaetsklinikum Leipzig AoeR

    Leipzig, Saxony, Germany

  • Semmelweis Egyetem

    Budapest, Hungary

  • Azienda Socio Sanitaria Territoriale Fatebenefratelli (Presidio Ospedale Sacco)

    Milan, Italy

  • DAI di Medicina Interna, Immunologia Clinica, Patologia Clinica, Malattie Infettive

    Naples, Italy

  • Azienda Ospedaliera Universitaria OO. RR. S. Giovanni di Dio e Ruggi D'Aragona

    Salerno, Italy

  • Hiroshima University Hospital

    Hiroshima, Japan

  • Kobe University Hospital

    Hyōgo, Japan

  • Amsterdam UMC

    Amsterdam, Netherlands

  • Universitair Medisch Centrum Groningen

    Groningen, Netherlands

  • UMC Utrecht

    Utrecht, Netherlands

  • NZOZ Homeo Medicus, Poradnia Alergologiczna

    Bialystok, Poland

  • "ALL-MED" Specjalistyczna Opieka Medyczna Medyczny Instytut Badawczy

    Wroclaw, Poland

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.